BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

July 28, 2014 7:00 AM UTC

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $5.79 to $167.04 last week after EMA accepted and granted accelerated assessment to an MAA for asfotase alfa to treat hypophosphatasia (HPP). The company expects to complete a rolling BLA submission to FDA for the product this fall.

Alexion also reported 2Q14 earnings that beat the Street, including $512.5 million in 2Q14 sales for Soliris eculizumab (see "EPS Watch," page 20)...